FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1968268802> ?p ?o ?g. }

• W1968268802 endingPage "138" @default.
• W1968268802 startingPage "133" @default.
• W1968268802 abstract "Controversies are still seen in the histological differential diagnosis of hyperplasia and well-differentiated endometrial carcinoma. Prediction of endometrial cancer in patients with hyperplasia with atypia, with the available markers has not been reliable yet. Hence these patients require more attention in the clinical management. Endometrial hyperplasia is proliferation of endometrial glands resulting in a higher gland : stroma ratio. Cytological atypia, which may progress to or co-exist with endometrial cancer and other pathological changes, result from estrogen stimulation unopposed by progesterone. Biomarkers whose expression is altered in cases of endometrial hyperplasia or cancer such as progesterone receptor, insulin-like growth factor I, retinaldehyde dehydrogenase type II, and secreted frizzled-related protein 4, seem to be promising to use as early-stage tumor markers. Mutation of PTEN is present in 83% of endometrial adenocarcinoma cases, making it the most frequent early molecular genetic alteration in type 1 endometrial tumors, which are generally associated with hyperplasia. p53 gene mutation is not found in endometrial hyperplasia, but researchers have detected this mutation in 20% of cases of endometrial carcinoma and 90% of cases of serous endometrial tumors. Cyclooxygenase-2 is important in tumorogenic transformation of hyperplasia. Expression of cyclooxygenase-2 decreases apoptosis, increases angiogenesis, and is related to invasiveness. Cyclooxygenase-2 expression increases significantly in cases of well-differentiated endometrial adenocarcinoma. Prostaglandin E2 is known to regulate aromatase gene expression and is the product of cyclooxygenase-2. The data about aromatase inhibitors are promising; in breast cancer patients, treatment with tamoxifen induces uterine abnormalities as early as 3 months after the initiation of therapy. In contrast, these abnormalities are not seen in patients who receive aromatase inhibitors and switched therapy after tamoxifen withdrawal may reverse tamoxifen-associated endometrial thickening." @default.
• W1968268802 created "2016-06-24" @default.
• W1968268802 creator A5018284030 @default.
• W1968268802 creator A5025625240 @default.
• W1968268802 creator A5044683401 @default.
• W1968268802 creator A5090532877 @default.
• W1968268802 date "2008-04-01" @default.
• W1968268802 modified "2023-10-14" @default.
• W1968268802 title "From endometrial hyperplasia to endometrial cancer: insight into the biology and possible medical preventive measures" @default.
• W1968268802 cites W1507820521 @default.
• W1968268802 cites W1832839964 @default.
• W1968268802 cites W1982071620 @default.
• W1968268802 cites W1984530482 @default.
• W1968268802 cites W1988827583 @default.
• W1968268802 cites W1992658805 @default.
• W1968268802 cites W1992963174 @default.
• W1968268802 cites W1997098766 @default.
• W1968268802 cites W2006398865 @default.
• W1968268802 cites W2016078791 @default.
• W1968268802 cites W2017521059 @default.
• W1968268802 cites W2026422116 @default.
• W1968268802 cites W2028850832 @default.
• W1968268802 cites W2044869180 @default.
• W1968268802 cites W2047518704 @default.
• W1968268802 cites W2067222685 @default.
• W1968268802 cites W2073325756 @default.
• W1968268802 cites W2074063177 @default.
• W1968268802 cites W2080491966 @default.
• W1968268802 cites W2092171701 @default.
• W1968268802 cites W2094242183 @default.
• W1968268802 cites W2097113048 @default.
• W1968268802 cites W2113190292 @default.
• W1968268802 cites W2117572744 @default.
• W1968268802 cites W2118510249 @default.
• W1968268802 cites W2129680759 @default.
• W1968268802 cites W2134137902 @default.
• W1968268802 cites W2142013294 @default.
• W1968268802 cites W2143931642 @default.
• W1968268802 cites W2145149010 @default.
• W1968268802 cites W2162128679 @default.
• W1968268802 cites W2167394623 @default.
• W1968268802 cites W2168240431 @default.
• W1968268802 cites W2169410595 @default.
• W1968268802 cites W2172094497 @default.
• W1968268802 cites W2336215030 @default.
• W1968268802 doi "https://doi.org/10.1097/cej.0b013e32811080ce" @default.
• W1968268802 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18287870" @default.
• W1968268802 hasPublicationYear "2008" @default.
• W1968268802 type Work @default.
• W1968268802 sameAs 1968268802 @default.
• W1968268802 citedByCount "71" @default.
• W1968268802 countsByYear W19682688022012 @default.
• W1968268802 countsByYear W19682688022013 @default.
• W1968268802 countsByYear W19682688022014 @default.
• W1968268802 countsByYear W19682688022015 @default.
• W1968268802 countsByYear W19682688022016 @default.
• W1968268802 countsByYear W19682688022017 @default.
• W1968268802 countsByYear W19682688022018 @default.
• W1968268802 countsByYear W19682688022019 @default.
• W1968268802 countsByYear W19682688022020 @default.
• W1968268802 countsByYear W19682688022021 @default.
• W1968268802 countsByYear W19682688022022 @default.
• W1968268802 countsByYear W19682688022023 @default.
• W1968268802 crossrefType "journal-article" @default.
• W1968268802 hasAuthorship W1968268802A5018284030 @default.
• W1968268802 hasAuthorship W1968268802A5025625240 @default.
• W1968268802 hasAuthorship W1968268802A5044683401 @default.
• W1968268802 hasAuthorship W1968268802A5090532877 @default.
• W1968268802 hasConcept C121608353 @default.
• W1968268802 hasConcept C126322002 @default.
• W1968268802 hasConcept C134018914 @default.
• W1968268802 hasConcept C142724271 @default.
• W1968268802 hasConcept C143998085 @default.
• W1968268802 hasConcept C190283241 @default.
• W1968268802 hasConcept C2775904963 @default.
• W1968268802 hasConcept C2776166826 @default.
• W1968268802 hasConcept C2777088508 @default.
• W1968268802 hasConcept C2777176818 @default.
• W1968268802 hasConcept C2777546739 @default.
• W1968268802 hasConcept C2777562237 @default.
• W1968268802 hasConcept C2777609662 @default.
• W1968268802 hasConcept C2777689261 @default.
• W1968268802 hasConcept C2781283455 @default.
• W1968268802 hasConcept C502942594 @default.
• W1968268802 hasConcept C530470458 @default.
• W1968268802 hasConcept C55493867 @default.
• W1968268802 hasConcept C71924100 @default.
• W1968268802 hasConcept C86554907 @default.
• W1968268802 hasConcept C86803240 @default.
• W1968268802 hasConceptScore W1968268802C121608353 @default.
• W1968268802 hasConceptScore W1968268802C126322002 @default.
• W1968268802 hasConceptScore W1968268802C134018914 @default.
• W1968268802 hasConceptScore W1968268802C142724271 @default.
• W1968268802 hasConceptScore W1968268802C143998085 @default.
• W1968268802 hasConceptScore W1968268802C190283241 @default.
• W1968268802 hasConceptScore W1968268802C2775904963 @default.
• W1968268802 hasConceptScore W1968268802C2776166826 @default.
• W1968268802 hasConceptScore W1968268802C2777088508 @default.

• next